Solabegron

Solabegron is a selective beta-3 adrenergic receptor agonist and small molecule drug developed primarily for the treatment of overactive bladder and irritable bowel syndrome. It acts by stimulating the beta-3 adrenergic receptor, leading to relaxation of bladder smooth muscle and increased bladder storage capacity. Additionally, it has been shown to produce visceral analgesia through somatostatin release from adipocytes. Solabegron was originally discovered by GlaxoSmithKline and later acquired by AltheRx, which became Velicept Therapeutics. The drug has reached Phase II clinical trials for both overactive bladder and irritable bowel syndrome but development for type 2 diabetes mellitus was discontinued[1][4][5][7].

Other names

Solabegron hydrochloride(R)-3'-((2-((2-(3-Chlorophenyl)-2-hydroxyethyl)amino)ethyl)amino)-[1,1'-biphenyl]-3-carboxylic acid